Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2015 Jul 15;25(14):2849-52. doi: 10.1016/j.bmcl.2015.04.092. Epub 2015 May 6.

Prostate tumor specific peptide-peptoid hybrid prodrugs.

Author information

1
Department of Global Medical Science, Sungshin University, Seoul 142-732, Republic of Korea.
2
Department of Bioengineering, Stanford University, Palo Alto, CA 94305, USA.
3
Department of Bioengineering, Stanford University, Palo Alto, CA 94305, USA. Electronic address: aebarron@stanford.edu.
4
Division of Liberal Arts and Sciences and Department of Chemistry, Gwangju Institute of Science and Technology, 123 Cheomdan gwagiro, Buk-gu, Gwangju 500-712, Republic of Korea. Electronic address: jseo@gist.ac.kr.

Abstract

Inspired by naturally occurring host defense peptides, cationic amphipathic peptoids provide a promising scaffold for anti-cancer therapeutics. Herein, we report a library of peptide-peptoid hybrid prodrugs that can be selectively activated by prostate cancer cells. We have identified several compounds demonstrating potent anti-cancer activity with good to moderate selectivity. We believe that these prodrugs can provide a useful design principle for next generation peptide-peptoid hybrid prodrugs.

KEYWORDS:

Anti-cancer; Antimicrobial peptides; Peptidomimetics; Peptoids; Prodrug; Prostate cancer

PMID:
26022845
DOI:
10.1016/j.bmcl.2015.04.092
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center